دورية أكاديمية
Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy
| العنوان: | Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy |
|---|---|
| المؤلفون: | Domingo, Pere (Domingo Pedrol), Mateo, María Gracia, Villarroya i Terrade, Joan, Cereijo Téllez, Rubén, Torres, Ferran, Domingo i Pedrol, Joan Carles, Campderrós Traver, Laura, Gallego-Escuredo, José M., Gutierrez, María del Mar, Mur, Isabel, Corbacho, Noemí, Vidal, Francesc, Villarroya i Gombau, Francesc, Giralt i Oms, Marta |
| المصدر: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) |
| بيانات النشر: | MDPI |
| سنة النشر: | 2022 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Resistència a la insulina, Síndrome metabòlica, Persones seropositives, Insulin resistance, Metabolic syndrome, HIV-positive persons |
| الوصف: | Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS−, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 13 p.; application/pdf |
| اللغة: | English |
| تدمد: | 2077-0383 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.3390/jcm11030549Test; Journal of Clinical Medicine, 2022, vol. 11, num. 3, p. 1-13; https://doi.org/10.3390/jcm11030549Test; http://hdl.handle.net/2445/185890Test; 720818 |
| الإتاحة: | https://doi.org/10.3390/jcm11030549Test http://hdl.handle.net/2445/185890Test |
| حقوق: | cc-by (c) Domingo, Pere (Domingo Pedrol) et al., 2022 ; https://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.262C85C5 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20770383 |
|---|